Abstract The anti-tumor activity of imidazolium salts is highly dependent upon the substituents on the nitrogen atoms of the imidazolium cation. We have synthesized and characterized a series of naphthalene-substituted imidazolium salts and tested them against a variety of non-smallcell lung cancer cell lines. Several of these complexes displayed anticancer activity comparable to cisplatin. These compounds induced apoptosis in the NCI-H460 cell line as determined by Annexin V staining, caspase-3, and PARP cleavage. These results strongly suggest that this class of compounds can serve as potent chemotherapeutic agents.
attributed to lung cancer. Lung cancer is divided into two major categories: small-cell lung carcinoma (SCLC) and non-small-cell lung carcinoma (NSCLC), with the latter accounting for 80 % of all diagnosed lung cancers (Siegel et al., 2012) . NSCLC is made up of several different types of lung cancers, including adenocarcinoma, squamous cell carcinoma, bronchoalveolar carcinoma, and large-cell carcinoma. Common treatments involve a mixture of organic and heavy metal-based drugs, such as cisplatin. These chemotherapeutic drugs can have devastating side effects on the patient, including kidney, liver, and nerve damage (Yao et al., 2007) . Additionally, resistance to chemotherapeutic agents ordinarily develops due to the diverse protein expression found in cancerous cells, leading to a relapse in a large number of treated patients (Katano et al., 2002) .
The necessity of reducing the toxic side effects of anticancer drugs and increasing their longevity by avoiding resistance has spurred the development of several new potential chemotherapies. One strategy that has been investigated to overcome both the issues of toxicity and resistance is the use of silver carbene complexes (SCCs) as chemotherapeutic agents. Silver, specifically the bioactive silver cation, has a long history as an efficacious antimicrobial agent, and N-heterocyclic carbenes have shown to be effective, relatively nontoxic ligands with which to deliver the silver cations (Garrison and Youngs, 2005; Garrison et al., 2001a, b; Kascatan-Nebioglu et al., 2006; Hindi et al., 2008; Ornelas-Megiatto et al., 2012) . Furthermore, bacterial resistance to silver has been infrequent, allowing the medicinal use of silver since the 1800s (Russel et al., 1994; Landsdown, 2002 Landsdown, , 2004 Lansdown and Williams, 2004) . To this point, the use of SCCs as potential anti-tumor agents has focused on lipophilic compounds derived from 4,5-dichloroimidazole Hindi et al., 2009a, b; Panzner et al., 2009; Lin et al., 2009) . Several of these complexes have shown in vitro anti-tumor activity at clinically relevant levels, spurring the investigation of additional, analogous compounds (Youngs et al., 2012a; Gautier and Cisnetti, 2012; Oehinger et al., 2013) .
Based on our anticancer studies on lipophilic SCCs, it was determined that several of the corresponding imidazolium salts also possessed potent anti-tumor activity. Imidazolium salts are the immediate precursors to all of the SCCs studied, as well as the primary degradation product of a majority of the complexes. This observation supported several recent reports of imidazolium salts displaying activity against cancer cell lines (Riduan and Zhang, 2013) . Tolcher et al. have discussed the suppression of survivin, an inhibitor of apoptosis, by a hydrophilic imidazolium salt. In this phase I human trial, Tolcher observed the inhibition of non-Hodgkin's lymphoma, prostate cancer, and minor inhibition of non-small-cell lung cancer lesions (Tolcher et al., 2008) . Serebrennikova et al. reported three novel imidazolium-based glycerolipids that induce apoptosis in chronic human promyelocytic leukemia cells (K562). These data suggest that at low concentrations, imidazolium salts disturb the cell cycle, but at higher concentrations, apoptosis is stimulated (Markova et al., 2010) . Malhotra has tested several long alkyl chain-containing imidazolium salts against a sizable panel of cancer cell lines and found high activity (Malhotra and Kumar, 2010) .
With the potential of imidazolium salts as anticancer agents well established, our focus has been the improvement of the lipophilic imidazolium salts. Although these systems have shown impressive anticancer activity, their principal drawback remains their limited solubility in water, which severely impairs the ability to administer these compounds systemically. Through the rational selection of substituents of the N-heterocycle, we have strived to synthesize the corresponding salts to have a higher solubility in water, while still maintaining the lipophilicity that is believed to contribute to their efficacy Li et al., 2010; Youngs et al., 2012b, c) . Additionally, by creating several analogs of an already effective lipophilic imidazolium salt, IC23 (Fig. 1) , and observing their anticancer activity, we hope to begin to decipher the mechanism of action of these compounds. In this paper, we report new lipophilic imidazolium and xanthinium salts derived from a variety of compounds containing an imidazole group, including their synthesis, characterization, and in vitro anticancer activity. Furthermore, we identified that the mechanism of cell death induced by IC23 is mediated through apoptosis.
Results and discussion
In Schemes 1, 2, 3, and 4, the synthetic routes of compounds 1-23 are outlined. Compounds 1-9 were prepared by stirring 4,5-dichloroimidazole with 1.1 equivalents of potassium hydroxide and one equivalent of the appropriate alkyl bromide or iodide in refluxing acetonitrile for 12-15 h to yield the corresponding monoalkylated imidazoles, which were stirred with one equivalent of (2-bromomethyl)naphthalene in refluxing acetonitrile for 12-15 h to generate the imidazolium salts in yields ranging from 20 to 67 % (Scheme 1; Figs. 2, 3, and 4). The symmetric compound 1,3-dibenzyl-4,5-dichloroimidazolium bromide (10) was synthesized by stirring 4,5-dichloroimidazole with 1.1 equivalents of potassium hydroxide and two equivalents of benzyl bromide, introduced in two separate additions to allow for the removal of the generated potassium bromide, in refluxing acetonitrile for a total of 3.5 h, producing 10 in a 42 % yield. The synthesis of the asymmetric compound 1-benzyl-4,5-dichloro-3-(napthalen-2-ylmethyl)imidazolium bromide (11) proceeded in a similar fashion. 4,5-Dichloroimidazole was stirred with 1.1 equivalents of potassium hydroxide and one equivalent of (2-bromomethyl)naphthalene in refluxing acetonitrile for 3 h to yield the monosubstituted imidazole. To this intermediate was added one equivalent of benzyl bromide, and the mixture was heated in refluxing acetonitrile for 8 h to give the imidazolium salt 11 in 33 % yield. With this asymmetric substitution, a ''scrambling'' of the substituents was observed when the reaction was allowed to proceed longer than 8 h, producing the desired compound 11, as well as the symmetric compounds 4,5-dichloro-1,3-bis (naphthalen-2-ylmethyl)imidazolium bromide (IC23) and 10. The symmetric compounds 1,3-bis(naphthalen-2-ylmethyl)imidazolium bromide (12) and 1,3-bis(naphthalen-2-ylmethyl)benzimidazolium bromide (13) were synthesized by stirring either imidazole or benzimidazole with 1.1 equivalents of potassium hydroxide and two equivalents of (2-bromomethyl)naphthalene, introduced in two separate additions to allow for the removal of the generated potassium bromide, in refluxing acetonitrile. Compounds 12 and 13 were produced in 35 and 84 % yield, respectively (Scheme 2; Figs. 5, 6). The xanthine-based imidazolium salt 1,3,9-trimethyl-7-(naphthalen-2-ylmethyl)xanthinium iodide (15) was synthesized by stirring theophylline and an excess of both potassium hydroxide and (2-bromomethyl)naphthalene in acetonitrile at room temperature for 2 days, which generated the monosubstituted product, 14. This intermediate Fig. 4 Thermal ellipsoid plot of the cationic portion of 6 with thermal ellipsoids drawn at 50 % probability. Hydrogen atoms and the bromide anion have been removed for clarity Fig. 3 Thermal ellipsoid plot of the cationic portion of 4 with thermal ellipsoids drawn at 50 % probability. Hydrogen atoms and the bromide anion have been removed for clarity Fig. 2 Thermal ellipsoid plot of the cationic portion of 2 with thermal ellipsoids drawn at 50 % probability. Hydrogen atoms and the bromide anion have been removed for clarity was stirred with a large excess of iodomethane in DMF heated to 80°C for 20 h to produce 15 in a 58 % yield (Scheme 3; Fig. 7 ). The monosubstituted imidazole 4,5-dichloro-1-(2-(naphthalen-1-yl)ethyl)-imidazole (16) was synthesized by stirring 4,5-dichloroimidazole with 1.1 equivalents of potassium hydroxide and one equivalent of 1-(2-bromoethyl)naphthalene in refluxing acetonitrile for 2.5 h. Compound 16 served as the immediate precursor to the imidazolium salts 4,5-dichloro-1,3-bis(2-(naphthalen-1-yl)ethyl)-imidazolium bromide (17), 4,5-dichloro-1-(2-(naphthalen-1-yl)ethyl)-3-(naphthalen-2-ylmethyl)-imidazolium bromide (18), and 3-benzyl-4,5-dichloro-1-(2-(naphthalen-1-yl)ethyl)-imidazolium bromide (19). In a sealed pressure vessel, 16 was stirred with an excess of 1-(2-bromoethyl)naphthalene in acetonitrile and heated to an external temperature of 120°C overnight to give 17 in a 48 % yield. Compounds 18 and 19 were synthesized by a similar procedure, as 16 was stirred with one equivalent of (2-bromomethyl)naphthalene or benzyl bromide in refluxing acetonitrile to generate the corresponding imidazolium salt in 77 and 44 % yield, respectively (Scheme 4; Figs. 8, 9) .
A related series of compounds was created from the monosubstituted imidazole 4,5-dichloro-1-(2-(naphthalen-2-yl)ethyl)-imidazole (20). Compound 20 was synthesized by the same procedure as the isomeric imidazole 16, with 2-(2-bromoethyl)naphthalene being used to generate 20 in 31 % yield. 4,5-Dichloro-1,3-bis(2-(naphthalen-2-yl)ethyl)-imidazolium bromide (21) and 4,5-dichloro-1-(2-(naphthalen-2-yl)ethyl)-3-(naphthalen-2-ylmethyl)-imidazolium bromide (22) were synthesized by the same method as their isomeric analogs, 17 and 18, respectively, with minor deviations. Compound 21 was produced in 41 % yield by the addition of an equimolar amount of 2-(2-bromoethyl)-naphthalene to 20. Compound 22 was produced in 52 % yield by the addition of (2-bromomethyl)naphthalene to 20 (Scheme 5; Figs. 10, 11).
The asymmetric imidazolium salt 4,5-dichloro-1-(naphthalen-2-ylmethyl)-3-(quinolin-2-ylmethyl)imidazolium bromide (23) was synthesized by stirring 4,5-dichloroimidazole and (2-chloromethyl)quinoline hydrochloride with a slight excess of potassium hydroxide in refluxing acetonitrile overnight to yield the monosubstituted imidazole. (2-Bromomethyl)naphthalene was added to the intermediate and stirred in refluxing acetonitrile for 3.5 h to generate 23 in 86 % yield (Scheme 6; Fig. 12 ). Thermal ellipsoid plot of the cationic portion of 13 with thermal ellipsoids drawn at 50 % probability. Hydrogen atoms, the bromide anion, and a disordered chloroform molecule have been removed for clarity Fig. 7 Thermal ellipsoid plot of the cationic portion of 15 with thermal ellipsoids drawn at 50 % probability. Hydrogen atoms and the iodide anion have been removed for clarity Fig. 8 Thermal ellipsoid plot of 16 with thermal ellipsoids drawn at 50 % probability. Hydrogen atoms have been removed for clarity Fig. 9 Thermal ellipsoid plot of the cationic portion of 17 with thermal ellipsoids drawn at 50 % probability. Hydrogen atoms and the bromide anion have been removed for clarity All symmetric and asymmetric imidazolium salts, as well as select monosubstituted imidazole precursors, were characterized by 1 H and 13 C NMR, mass spectrometry, elemental analysis, and melting point determination. In addition, the structures of imidazolium salts 2, 4, 6, 12, 13, 15, 17, 21 and the precursors 16 and 20 were determined by single-crystal X-ray diffraction.
The 1 H NMR spectra of all imidazolium and xanthinium salts show a characteristic downfield resonance from the C 2 -H proton in the range of 9.38-10.15 ppm due to the positive charge carried by the NC 2 HN portion of the imidazolium cation. These chemical shifts are consistent with those observed in the 1 H NMR spectra of structurally similar compounds. In the 13 C NMR spectra, the corresponding NC 2 N carbon resonances do not undergo a downfield shift as substantial as that observed in the 1 H NMR spectra; however, the number of and chemical shifts of the resonances in each 13 C NMR spectrum fully support the formation of the desired products. Additionally, ESI mass spectrometry in the positive mode was performed on the imidazolium salts, and the identity of each product was strongly supported by the presence of the corresponding [M-Br] ? or [M-I] ? fragment in its spectrum. The melting points of the imidazolium salts range from 155 to 195°C, with the exception of 13, which melts at a significantly higher temperature (261-263°C).
In an attempt to synthesize asymmetric imidazolium salts containing aromatic substituents, an unexpected result was obtained. The addition of an equimolar amount of benzyl bromide to the reaction mixture presumably containing 4,5-dichloro-1-(naphthalen-2-ylmethyl)imidazole yielded the expected asymmetric imidazolium salt 11, as well as the symmetric salts IC23 and 10. In the 1 H NMR spectrum, three separate downfield resonances in the C 2 -H region suggested the presence of three unique imidazolium salts, and two of the chemical shift values were identical to those observed in the spectra of pure samples of IC23 and 10. The identities of the three salts were further supported by positive mode ESI mass spectrometry data, which gave peaks that corresponded to the expected [M-Br] ? fragment of 10, 11, and IC23. These results suggested that the substituents of these imidazolium salts have some degree of lability.
In order to confirm that the substituents of 10, 11, and IC23 can undergo elimination and subsequent ''scrambling,'' an analytically pure sample of IC23 was dissolved in acetonitrile and an equimolar amount of benzyl bromide was added. After refluxing the mixture overnight, the products were characterized by 1 H NMR spectroscopy. The spectrum showed the resonances for 10, 11, and IC23 previously observed in the synthesis of 11. The addition of an equimolar amount of (2-bromomethyl)naphthalene to an analytically pure sample of 10 and subsequent heating at reflux resulted in the same mixture of products, as identified by 1 H NMR spectroscopy, indicating some degree of reversibility in these reactions (Fig. 13) . Compound 11 was eventually isolated by following the progress of the reaction between 4,5-dichloro-1-(napthalen-2-ylmethyl)-imidazole and benzyl bromide by 1 H NMR spectroscopy. When the reaction was allowed to proceed for 8 h, only 11 was isolated. At reaction times longer than 8 h, the 1 H NMR spectra of aliquots of the reaction mixture indicated the presence of multiple imidazolium salts.
Reactions similar to those previously discussed were performed on the symmetric imidazolium salts 12 and 13 and the asymmetric xanthinium salt 15. Analytically pure samples of these three compounds, each containing at least one naphthylmethyl substituent, were dissolved in an appropriate solvent and refluxed overnight with an equimolar amount of benzyl bromide. Interestingly, the 1 H NMR spectra of the resulting products contained only one downfield resonance that could be attributed to the C 2 -H (or C 8 -H for the xanthinium salt) proton, indicating that the naphthylmethyl substituents remained bound to the Nheterocycle. This result suggests that electron withdrawing groups off of the C 4 and C 5 atoms (Cl in IC23, 10, and 11) may be facilitating the observed reversibility of these reactions. The substituents of the C 4 and C 5 atoms have a large influence on the electronics of the front portion of the imidazole, as evidenced by the stability studies of metal N-heterocyclic carbene complexes, making this a reasonable theory . The notion that electronics are playing a significant role in this observed reversibility is further supported by the synthesis of 23, an asymmetric imidazolium salt containing both a naphthylmethyl and a quinolylmethyl substituent. Although 23 is based on 4,5-dichloroimidazole, it can be synthesized in high yield as the only product with no evidence of the formation of IC23 or the bis-quinoline imidazolium salt. The presence of the nitrogen atom provides some degree of stability for the quinolylmethyl substituent, allowing for the formation of the asymmetric product.
It is also of note that the observed reversibility affects only aromatic substituents with a methyl linker. Compounds 1-9, each containing an alkyl substituent, were the only imidazolium salts detected in their respective syntheses. Furthermore, a series of asymmetric compounds containing ethylnaphthalene substituents, with the linker in both the 1 and 2 positions of naphthalene, was synthesized without any observed reversibility. Compounds 18, 19, and 22 were all synthesized in moderate to good yields as the only imidazolium salt detected, despite the presence of C l atoms as the C 4 and C 5 substituents. IC23 has displayed anticancer activity against several cancer cell lines when applied in single-digit micromolar concentrations despite its severe lack of solubility in water (\0.1 mg/mL), which is problematic for the systemic delivery of the complex. We believe the activity may be a result of the hydrophobic nature of the substituents, specifically the two naphthylmethyl groups. The aromaticity and planarity of these groups are traits shared by several other anticancer agents that are efficacious due to their intercalation into the base pairs of DNA and introduce structural distortions that inhibit transcription and replication.
Due to the low water solubility of these imidazolium salts, it was difficult to determine the amount of compound that would dissolve into water. A saturated solution of the compound was stirred for several hours. The solution was passed through a syringe with a filter attached to remove any of the undissolved solid. A known amount of this solution was added to a pre-weighed round bottom flask. The solvent was evaporated to dryness by rotary evaporation. The mass of the flask was compared to the mass of the preweighed flask to determine the degree of water solubility. Several analogs of IC23 were synthesized in an effort to increase the water solubility of the complexes relative to IC23 while maintaining the anti-tumor efficacy.
Similar to IC23, 1-9 are derived from 4,5-dichloroimidazole and contain one naphthalene group in order to allow for possible interaction with DNA base pairs; however, the second substituent was replaced with alkyl chains of varying length. These alkyl chains allow the molecule to maintain its hydrophobic nature, and the replacement of a naphthalene substituent reduces the stabilizing pi-stacking interactions, which can exclude solvent molecules. As a result, the water solubility of the compounds was markedly improved from that of IC23, and a trend was observed. The highest water solubility was observed for 1, containing an ethyl substituent, at 13.5 mg/mL. Compound 3, with an isopropyl substituent, also displayed a large increase in water solubility at 10.8 mg/mL. Compounds 2 and 4, containing a propyl and butyl chain, respectively, showed moderate water solubility at 5.2 and 5.7 mg/mL. As the alkyl chain length was increased, the water solubility of the compounds decreased, presumably as a result of the increase in intermolecular forces between the longer alkyl chains acting in a similar manner to the p-p interactions of naphthalene groups.
In a separate attempt to confer water solubility to IC23 analogs, compounds 17 and 18 were synthesized, with each containing at least one ethyl linker between the N-heterocycle and the naphthalene ring, which was bound in the C 1 position. The rationale behind the design of these complexes centered on the introduction of additional degrees of freedom via the introduction of the ethyl, rather than methyl, linker. The naphthalene portion of the substituent has additional freedom with the ethyl linker compared to the methyl linker, which can reduce the intermolecular pistacking that likely occurs (pi-stacking has been observed in the solid state for similar molecules). Intermolecular pistacking may also be perturbed by the orientation of the naphthalene bound in the C 1 position, rather than in the C 2 position as in IC23. The water solubility of 17 was mildly increased from that of IC23 to 0.4 mg/mL. Compound 18, containing one naphthylethyl and one naphthylmethyl substituent, did not show a significant increase in water solubility compared to IC23. Compound 21, the symmetric isomeric analog to 17, was synthesized to determine the effects of changing the point of attachment of the linker group to the naphthalene ring. A modest increase in water solubility was obtained by including a heteroatom in the aromatic substituent. The inclusion of a quinoline group bound with a methyl linker in 23 increased the solubility of the compound relative to IC23 to 0.9 mg/mL. The increase in water solubility is believed to be a consequence of the inclusion of a hydrogen bond acceptor into the fused aromatic substituent, allowing for a greater interaction of solvent molecules with the compound. The addition of the nitrogen atom does not perturb the planarity of the aromatic system, allowing the substituent to maintain its ability to possibly intercalate into other planar environments.
A compound derived from xanthine also demonstrated a significant increase in water solubility. Xanthine and several of its derivatives possess a high degree of water solubility, are relatively nontoxic, and have demonstrated clinical significance as treatments for several pulmonary ailments. A naphthylmethyl substituent was added to the xanthine derivative theophylline to yield the imidazolium salt 15, which has solubility in water at 2.6 mg/mL.
The previous results demonstrate that one of the major drawbacks of the efficacious imidazolium salt IC23, a lack of water solubility and resulting inability to deliver the compound systemically, can be remedied using several different strategies. The analogous compounds discussed have also been analyzed for their in vitro anticancer activity.
The in vitro anticancer activity of 1-23 against the NSCLC cell lines NCI-H460, NCI-H1975, and HCC827 was evaluated, and the results are summarized in Table 1 . The cells were exposed to compounds for 72 h after which a standard MTT assay was used to determine the cell viability. From these data, IC 50 values were determined, where the IC 50 value denotes the median concentration of the compound that causes a 50 % inhibition in cell viability, relative to control cells. Several of the imidazolium salts displayed IC 50 values in the single-digit micromolar range against one or more of the NSCLC lines, which is on par with the activity of cisplatin. Imidazolium salts 1-9, each containing a naphthylmethyl substituent and a varying alkyl substituent, varied greatly in their effectiveness. Compounds 1-3 showed little to no efficacy against any of the cell lines, despite having the highest solubility in water, with IC 50 values ranging from 19 lM to greater than 30 lM against the panel of cancer cell lines. As the alkyl substituent was lengthened, the efficacy of the corresponding compounds began to improve but the solubility decreased with the added lipophilicity. Compound 5 displayed IC 50 values of 10-12 lM, while the IC 50 values of 6-9 were less than or equal to 10 lM. These values are in the same range as those observed for cisplatin (H460-3 lM; H1975-10 lM; HCC827-4 lM) and IC23 (5 lM; 6 lM; 8 lM). In this series of compounds, 1-9 have either sufficient solubility or comparable activity to IC23, but none have both of these characteristics. There needs to be a balance between hydrophilicity and lipophilicity, which is not met with 1-9 when exchanging one of the naphthylmethyl groups for an alkyl chain.
The symmetric imidazolium salt 10 containing two benzyl substituents did not demonstrate any relevant anticancer activity, with an IC 50 value of greater than 30 lM for all three cell lines. The lack of activity demonstrated by 10 suggests that an extended planar, aromatic system as a substituent, is essential to anticancer efficacy in NSCLC cell lines. This notion is supported by 11, in which one of the benzyl substituents in 10 has been replaced with a naphthylmethyl group. The IC 50 values of 11 fall between 12 and 15 lM against the three cell lines, a substantial improvement over the activity of 10. Anticancer activity near that of IC23 and cisplatin was restored in 12 (H460-4 lM; H1975-6 lM; HCC827-9 lM) and 13 (3 lM; 4 lM; 5 lM), both of which contain two methylnaphthyl substituents.
The trisubstituted xanthine precursor 14 was tested against the panel of cancer cells and showed moderate efficacy, especially against the H460 (8 lM) and H1975 (12 lM) lines. This result demonstrated that the cationic nature of the imidazole or imidazole-containing molecule was not a requirement for anticancer activity. In fact, the formation of xanthinium salt via the methylation of 14 yielded 15, which had no observable anti-tumor activity against the three cell lines. Compound 15 had increased water solubility compared to IC23 but severely decreased activity. These results are not surprising considering compound 1, with one naphthylmethyl and one methyl group bound to the imidazole base, had high solubility but was also rendered inactive.
The imidazolium salts containing naphthalene substituents bound in the 1 or 2 position of the naphthalene ring with either methyl or ethyl linkers demonstrated promising anticancer activity against all three lines tested. The IC 50 values of 18 were all in the range of cisplatin and IC23 at 5 lM, 6 lM, and 7 lM for the H460, H1975, and HCC827 lines, respectively. Also in this range were 17 (8 lM; 8 lM; 11 lM), 21 (8 lM; 8 lM; 8 lM), and 22 (4 lM; 7 lM; 9 lM). Consistent with earlier results, the benzyl-substituted salt 19 possessed IC 50 values (12 lM, 14 lM, [30 lM) noticeably higher than those of the naphthalene-containing compounds. Although 17 and 18 had similar IC 50 values to IC23, the solubilities were not significantly higher than IC23. Therefore, changing the methyl linker to an ethyl linker is not a sufficient modification to increase the solubility.
Compound 23 demonstrated that the inclusion of a heteroatom into the extended planar, aromatic system, did not substantially alter the anticancer activity of the system. The IC 50 values of 23 were very similar to that of IC23 at 10 lM (H460), 5 lM (H1975), and 9 lM (HCC827). The added hydrogen-bonding acceptor caused a dramatic increase in the aqueous solubility with at least a 10-fold increase from IC23 while maintaining the high activity. Various functional groups had drastic effects on the solubility and activity of these imidazolium salts, but it is clear that there needs to be a balance between hydrophilicity and lipophilicity for the compound to remain active while achieving solubility at clinically relevant levels.
Treatment of H460 cells with the listed imidazolium compounds causes morphological changes that include cell shrinking, rounding, and the eventual detachment of the cells from the culture plate as early as 1 h after the treatment (Fig. 14) . The efficacy of these compounds as determined by MTT assay is comparable to cisplatin that we use as a standard chemotherapeutic drug in not only H460 cells (Fig. 15) , but also in H1975 and HCC827 NSCLC lines. The IC 50 data shown in the table above strongly suggest that these compounds are effective against the selected NSCLC lines. In an attempt to analyze the mechanism of cell death induced by the IC23, an Annexin V (conjugated to FITC) apoptosis detection kit was employed. This assay detects phosphatidylserine (PS) expressed on the surface of apoptotic cells and fluoresces green after interacting with the labeled Annexin V. During early apoptosis, membrane asymmetry is lost, and PS translocates from the cytoplasmic side of the membrane to the external leaflet. Propidium iodide (PI), the counterstain used in this assay, has the ability to cross only compromised membranes to intercalate into the DNA. Therefore, PI is used to detect the different stages of apoptosis by the absence or presence of red fluorescence (Van Engeland et al., 1998) . Figure 16 shows the progression of apoptosis caused by the introduction of compound IC23 into the growth medium at increasing time frames. As a comparison, negative and positive controls were tested alongside the IC23-treated cells. The negative control consisted of H460 cells grown in medium, and H460 cells grown in the presence of cisplatin constituted the positive control, as cisplatin is a known inducer of apoptosis. Treatment of cells with IC23 for a period of 1 h revealed cells in the early stage of apoptosis. These results were comparable to the cisplatin positive control images after treatment for 6 h. Cells treated with IC23 for a period of 3 h showed latestage apoptotic cells based on the visualization of both red and green fluorescence. Blebbing, a common indicator of apoptosis, was able to be visualized at this time point (Figs. 16d, 17 ). After treatment of IC23 for 6 h, imaged cells showed both red and green fluorescence. This combined with the absence of blebbing lead to the conclusion that these cells were in the end stage of apoptosis and were no longer viable. These results indicate that treatment of H460 cells with IC23 induces apoptosis at a faster rate than what is observed with cisplatin.
In a similar experiment, H460 cells were treated with the IC23 analog 12, which employs hydrogen in the C 4 and C 5 positions rather than chlorine. While cells could be visualized in the early stages of apoptosis, this was not seen until the latest time period at 6 h. These cells were relatively comparable to the cisplatin-treated cells visualized at the same time period. Treatment with 12 at 1 and 3 h was similar to the control cells. When comparing these cells to the IC23-treated cells, it is obvious that while 12 can cause H460 cells to begin the early stages of apoptosis, it takes a longer time frame to do so than IC23. This experiment shows that while there may be a difference in time needed for full effect of naphthalene-substituted analogs, they do cause cells to go through the process of apoptosis.
To further confirm that these compounds induce apoptotic cell death, in parallel experiments, we also analyzed the expression and cleavage of apoptotic proteins caspase-3 and PARP cleavage by Western blotting (Fig. 18) . We found the presence of full-length PARP and procaspase-3 proteins with no cleaved products in the control cell lysates indicating the absence of apoptosis. However, cell lysates treated with IC23 at 12 h showed the presence of cleaved PARP and substantial reduction in the levels of procaspase-3 confirming apoptotic cell death. A possible reason that we could not detect any cleaved caspase-3 could be explained by its short half-life in the cells. Cell lysates from cells treated with cisplatin served as a control. Further, equal protein loading in the samples was confirmed by stripping the blots and probing with a housekeeping protein, GAPDH, and the levels of GAPDH were equal in all the analyzed samples.
Conclusions
In this paper, we have presented a series of novel imidazolium salts that have anticancer activity comparable to that of cisplatin as tested on the three NSCLC cell lines NCI-H460, NCI-H1975, and HCC827 using MTT assays. The efficacy of these compounds is tied to the interaction Further studies based on the morphological changes in tested cells showed that IC23 produced similar staining patterns using an Annexin V assay, but at different time frames as cisplatin, a known apoptosis inducer. Western blot staining of NCI-H460 cells showed IC23-induced PARP-1 cleavage and a reduction in procaspase-3 as compared to cisplatin. The Annexin V, caspase-3, and PARP-1 results indicate that IC23 is inducing the apoptotic pathway in the cancer cells.
In whole, these results show that imidazolium salts with naphthylmethyl substituents should be studied further to understand their mechanism of action and possible uses as chemotherapeutics agents.
Experimental details

General considerations
All reactions were carried out under aerobic conditions unless otherwise specified. Benzimidazole, imidazole, 4,5-dichloroimidazole, and the alkyl halides were purchased from Alfa Aesar. 2-(Bromomethyl)naphthalene was purchased from Waterstone Technologies. 1-(2-Bromoethyl)naphthalene, 2-(naphthalen-1-yl)ethanol and 2-(naphthalen-2-yl)ethanol were purchased from Sigma-Aldrich. 1-(2-Bromoethyl)naphthalene and 2-(2-bromoethyl)naphthalene were synthesized via a literature procedure (Ellames and Herbert, 2010) . All solvents were purchased from Fisher Scientific and used without further purification. All reagents were used as received without further purification. Melting points were obtained on a MelTemp apparatus. 1 H and 13 C NMR spectra were collected on a Varian 500 MHz instrument with all spectra referenced to residual deuterated solvents (DMSO-d 6 : 2.50 ppm). Mass spectrometry was performed by the University of Akron mass spectrometry laboratory. Elemental analysis was performed by the Microanalysis Laboratory at University of Illinois at Urbana-Champaign.
Crystals of the compounds were coated in paratone oil, mounted on a CryoLoop, and placed on a goniometer under a stream of nitrogen. Crystal structure data sets were collected on a Bruker APEX CCD diffractometer with graphitemonochromated Mo K a radiation (k = 0.71073 Å ) or a Bruker APEX II Duo CCD system equipped with a Cu ImuS microfocus source (k = 1.54178 Å ). The unit cells were determined by using reflections from three different orientations. The data sets were integrated using SAINT (Bruker, 
1997, 2007
). An empirical absorption correction and other corrections were applied to the data sets using multi-scan SADABS (Ellames and Herbert, 2010) . Structure solution, refinement, and modeling were accomplished by using the Bruker SHELXTL package (Bruker, 1997; Sheldrick, 2008) . The structures were determined by full-matrix least-squares refinement of F 2 and the selection of the appropriate atoms from the generated difference map. Hydrogen atom positions were calculated, and U iso (H) values were fixed according to a riding model.
Cell culture
All cell lines were grown in RPMI-1640 medium supplemented with 10 % fetal bovine serum and maintained at 37°C in humidified 5 % CO 2 environment, unless otherwise stated.
MTT assay
The human cancer cell lines NCI-H460, NCI-H1975, and HCC827 were grown to confluency and then plated in 96-well plates at 5,000-7,000 cells per well and incubated for 24 h. Tested compounds and blanks were then suspended in a 1 % DMSO/water solution and diluted into cell culture medium to the desired concentrations. Medium was removed and replaced with fresh medium containing the test compounds (six replicates each in triplicate). The plates were allowed to incubate for 72 h, after which the optional MTT protocol was followed. MTT (10 lL) in PBS was added to each well, and the plates were incubated for 4 h. The medium was carefully removed, and 100 lL of DMSO was added per well. The optical density of each well was read at 540 nm on a SpectraMax microplate reader.
Cell lysis, gel electrophoresis, and immunoblotting
NCI-H460 cells (1 9 10 5 cells per well) were grown to confluency in a 6-well plate, using RPMI-1640 medium supplemented with 10 % fetal bovine serum and 1 % penicillin-streptomycin, and then serum-starved for 24 h. Cells were stimulated with indicated compounds for the indicated periods of time and lysed with ice-cold lysis buffer (50 mM Tris [pH 7.5], 1 mM EDTA, 1 mM EGTA, 1 mM Na 3 VO 4 , 1 % Triton X-100, 50 mM NaF, 5 mM sodium pyrophosphate, 10 mM sodium glycerophosphate, 4 mg/mL Leupeptin, and 30 mg/mL phenylmethanesulfonyl-fluoride, PMSF) supplemented with protease inhibitor cocktail (Roche) and phosphatase inhibitor cocktail (Pierce) as described earlier . Briefly, cell lysates were boiled at 100°C for 5 min in a sample buffer [62 mM Tris (pH 6.8), 1.0 % SDS, 10 % glycerol, 15 mg/mL dithiothreitol, and 0.05 % bromophenol blue]. Equal amount of lysates was subjected to SDS-PAGE on 4-12 %-gels (Bio-Rad).
The separated proteins were electrophoretically transferred to a PVDF membrane. All membranes were blocked for 1 h with 5 % nonfat dried milk in TBS containing 0.05 % Tween 20 (TBS-T) at room temperature and then incubated with a primary antibody overnight at 4°C. A 1:1,000 dilution of PARP, caspase-3 (cell signaling), and GAPDH (Fitzgerald) primary antibodies was used. Membranes were washed extensively in TBS-T and incubated with a horseradish-peroxidase-linked goat anti-rabbit antibody (1:5,000) for 1 h at room temperature. Thereafter, the membrane was again washed extensively, incubated with ECL Western blot detection reagents (GE Healthcare), and finally, the bands were visualized using an imager (Protein Simple Ò ). Blots were stripped and reprobed with GAPDH antibody for normalization.
Annexin V assay
The Annexin V assay was conducted using the components of a FITC Annexin V Apoptosis Detection Kit I (BD Biosciences). The NCI-H460 cell line was grown in 6-well plates at a density of 1 9 10 5 cells per well. After allowing cells to adhere overnight, they were treated with cisplatin Note that visualization of caspase-3 could be limited by its short halflife and IC23 at a concentration of 40 lM. Cisplatin and IC23 were first solubilized in a 1 % DMSO/water solution and were further diluted to the aforementioned concentration in culture medium. The first treatment consisted of aspirating off medium of a 6-well plate and replacing with fresh medium for control cells, cisplatin supplemented medium for cisplatin-treated cells, and IC23 supplemented medium for IC23-treated cells (2 wells per treatment type). The remaining IC23 treatments were conducted in the same manner at their respective times. After treatment, the medium was aspirated, and cells were washed twice with cold PBS. The provided 109 binding buffer was diluted to 19, and 300 lL was added to each well. Subsequently, 15 lL each of the provided FITC Annexin V and PI was also added to each well. The plates were incubated for 15 min on a platform shaker while covered with aluminum foil at room temperature. After this time, the binding buffer was aspirated from the wells, and 1 mL of the 19 binding buffer was added to each well for imaging. The fluorescence microscope used was an EVOS fl Digital Inverted Microscope with the 109 and 209 objectives.
Synthesis of 4,5-dichloro-1-ethyl-3-(naphthalen-2-ylmethyl)-imidazolium bromide (1) 4,5-Dichloroimidazole (1.23 g, 9.0 mmol) was dissolved in 27 mL of acetonitrile, potassium hydroxide (0.61 g, 9.9 mmol) was added, and the mixture was stirred for 0.5 h. Bromoethane (0.66 mL, 9.0 mmol) was added, and the solution was refluxed overnight. The solution was filtered hot to remove a white precipitate (presumed to be KBr), (2-bromomethyl)naphthalene (1.98 g, 9.0 mmol) was added, and the mixture was refluxed overnight. The mixture was allowed to cool to room temperature, resulting in a white precipitate that was isolated by filtration and air-dried. (0.71 g, 20 % yield) . 49.6; H, 3.8; N, 7 Synthesis of 4,5-dichloro-3-(naphthalen-2-ylmethyl)-1-propylimidazolium bromide (2) 4,5-Dichloroimidazole (1.23 g, 9.0 mmol) was dissolved in 27 mL of acetonitrile, potassium hydroxide (0.61 g, 9.9 mmol) was added, and the mixture was stirred for 0.5 h. 1-Iodopropane (0.88 mL, 9.0 mmol) was added, and the solution was refluxed overnight. The solution was filtered hot to remove a white precipitate (presumed to be KI), 2-bromomethylnaphthalene (1.98 g, 9.0 mmol) was added, and the mixture was refluxed overnight. The mixture was allowed to cool to room temperature, resulting in a yellow precipitate that was isolated by filtration and air-dried (1.13 g, 31 % yield Synthesis of 4,5-dichloro-1-isopropyl-3-(naphthalen-2-ylmethyl)imidazolium bromide (3) 4,5-Dichloroimidazole (1.23 g, 9.0 mmol) was dissolved in 27 mL of acetonitrile, potassium hydroxide (0.61 g, 9.9 mmol) was added, and the mixture was stirred for 0.5 h. 2-Iodopropane (0.88 mL, 9.0 mmol) was added, and the solution was refluxed overnight. The solution was filtered hot to remove a white precipitate (presumed to be KI), (2-bromomethyl)naphthalene (1.98 g, 9 mmol) was added, and the mixture was returned to reflux overnight. The mixture was then allowed to cool to room temperature, resulting in a white crystalline solid that was isolated by filtration and air-dried (1. Synthesis of 1-butyl-4,5-dichloro-3-(naphthalen-2-ylmethyl)-imidazolium bromide (4) 4,5-Dichloroimidazole (1.23 g, 9.0 mmol) was dissolved in 27 mL of acetonitrile, potassium hydroxide (0.61 g, 9.9 mmol) was added, and the mixture was stirred for 0.5 h. 1-Iodobutane (1 mL, 9.0 mmol) was added, and the solution was refluxed overnight. The solution was filtered hot to remove a white precipitate (presumed to be KI), (2-bromomethyl)naphthalene (1.98 g, 9.0 mmol) was added, and the mixture was refluxed overnight. The mixture was then allowed to cool to room temperature, resulting in a yellow precipitate that was isolated by filtration and air-dried (1.96 g, 53 % yield). Mp: 160-163°C. Found: C, 52.3; H, 4.6; N, 6.6 Calc. for C 18 H 19 Br 1 Cl 2 N 2 : C, 52.2; H, 4.6; N, 6.8 %.
1 H NMR (500 MHz, DMSO-d 6 ) d = 9.66 (1H, s, NCHN Crystal data for 4 C 17 H 17 Cl 2 N 2 ÁBr, M = 400.14, triclinic, a Synthesis of 4,5-dichloro-3-(naphthalen-2-ylmethyl)-1-pentylimidazolium bromide (5) 4,5-Dichloroimidazole (1.23 g, 9.0 mmol) was dissolved in 27 mL of acetonitrile, potassium hydroxide (0.61 g, 9.9 mmol) was added, and the mixture was stirred for 0.5 h. 1-Bromopentane (1.1 mL, 9.0 mmol) was added, and the solution was refluxed overnight. The solution was filtered hot to remove a white precipitate (presumed to be KBr), (2-bromomethyl)naphthalene (1.98 g, 9.0 mmol) was added, and the mixture was refluxed overnight. The mixture was then allowed to cool to room temperature, resulting in a yellow precipitate that was isolated by filtration and air-dried (1.79 g, 49 % yield). Mp: 168-169°C. Found: C, 53.1; H, 4.7; N, 6.4 Calc. for C 19 H 21 Cl 2 N 2 Br 1 : C, 53.3; H, 4.9; N, 6.5 %.
1 H NMR (500 MHz, DMSO-d 6 ) d = 9.66 (1H, s, NCHN), 8.02 (4H, m, Ar), 7.57 (3H, m, Ar), 5.66 (2H, s, NCH 2 ), 4.24 (2H, t, NCH 2 ), 1.80 (2H, tt, CH 2 ), 1.37 (2H, tq, CH 2 ), 0.93 (3H, t, CH 3 ).
13 C{ 1 H} NMR (125 MHz, DMSO-d 6 ) d = 136.4 (NCN), 132.8 (Ar), 132.6 (Ar), 130.0 (Ar), 128.8 (Ar), 127.8 (Ar), 127.7 (Ar), 127.6 (Ar), 126.8 (Ar), 126.7 (Ar), 125.5 (Ar), 120.9 (Ar), 114.1 (Ar), 112.9 (Ar), 51.6 (CH 2 ), 48.5 (CH 2 ), 27.8 (CH 2 ), 27.4 (CH 2 ), 21.4 (CH 2 ), 13.6 (CH 3 Synthesis of 4,5-dichloro-1-hexyl-3-(naphthalen-2-ylmethyl)-imidazolium bromide (6) 4,5-Dichloroimidazole (1.23 g, 9.0 mmol) was dissolved in 27 mL of acetonitrile, potassium hydroxide (0.61 g, 9.9 mmol) was added, and the mixture was stirred for 0.5 h. 1-Bromohexane (1.26 mL, 9.0 mmol) was added, and the solution was refluxed overnight. The solution was filtered hot to remove a white precipitate (presumed to be KBr), (2-bromomethyl)naphthalene (1.98 g, 9.0 mmol) was added, and the mixture was refluxed overnight. The mixture was then allowed to cool to room temperature, resulting in a yellow precipitate that was isolated by filtration and air-dried (2.57 g, 65 % yield Synthesis of 4,5-dichloro-1-heptyl-3-(naphthalen-2-ylmethyl)-imidazolium bromide (7) 4,5-Dichloroimidazole (1.23 g, 9.0 mmol) was dissolved in 27 mL of acetonitrile, potassium hydroxide (0.61 g, 9.9 mmol) was added, and the mixture was stirred for 0.5 h. 1-Bromoheptane (1.41 mL, 9.0 mmol) was added, and the solution was refluxed overnight. The solution was filtered hot to remove a white precipitate (presumed to be KBr), (2-bromomethyl)naphthalene (1.98 g, 9.0 mmol) was added, and the mixture was refluxed overnight. The mixture was then allowed to cool to room temperature, resulting in a light yellow precipitate that was isolated by filtration and air-dried (2.73 g, 67 % yield). 55.9; H, 5.4; N, 5.9 Calc. for C 21 H 25 Synthesis of 4,5-dichloro-3-(naphthalen-2-ylmethyl)-1-nonylimidazolium bromide (8) 4,5-Dichloroimidazole (1.23 g, 9.0 mmol) was dissolved in 27 mL of acetonitrile, potassium hydroxide (0.61 g, 9.9 mmol) was added, and the mixture was stirred for 0.5 h. 1-Bromononane (1.72 mL, 9.0 mmol) was added, and the solution was allowed to reflux overnight. The solution was filtered hot to remove a white precipitate (presumed to be KBr), (2-bromomethyl)naphthalene (1.98 g, 9.0 mmol) was added, and the mixture was refluxed overnight. The mixture was then allowed to cool to room temperature, resulting in a yellow/ white precipitate that was isolated by filtration and airdried (2.73 g, 56 % yield 
4).
Synthesis of 4,5-dichloro-1-dodecyl-3-(naphthalen-2-ylmethyl)-imidazolium bromide (9) 4,5-Dichloroimidazole (1.23 g, 9.0 mmol) was dissolved in 27 mL of acetonitrile, potassium hydroxide (0.61 g, 9.9 mmol) was added, and the mixture was stirred for 0.5 h. 1-Bromododecane (2.16 mL, 9.0 mmol) was added, and the solution was refluxed overnight. The solution was filtered hot to remove a white precipitate (presumed to be KBr), (2-bromomethyl)naphthalene (1.98 g, 9.0 mmol) was added, and the mixture was refluxed overnight. The mixture was then allowed to cool to room temperature, resulting in a yellow/white precipitate that was isolated by filtration and air-dried (2.22 g, 47 % yield). 59.5; H, 6.7; N, 5 
Synthesis of 1,3-dibenzyl-4,5-dichloroimidazolium bromide (10) 4,5-Dichloroimidazole (1.37 g, 10 mmol) was dissolved in 10 mL of acetonitrile, potassium hydroxide (0.617 g, 11 mmol) was added, and the mixture was refluxed for 0.5 h. Benzyl bromide (1.71 g, 10 mmol) was added to the solution and refluxed for 2.5 h. The solution was filtered hot to remove a white precipitate (presumed to be KBr), a second equivalent of benzyl bromide (1.71 g, 10 mmol) was added, and the mixture was refluxed for 1 h. Synthesis of 1-benzyl-4,5-dichloro-3-(naphthalen-2-ylmethyl)-imidazolium bromide (11) 4,5-Dichloroimidazole (0.68 g, 5.0 mmol) was dissolved in 10 mL of acetonitrile, potassium hydroxide (0.31 g, 5.5 mmol) was added, and the mixture was stirred for 1 h. (2-Bromomethyl)naphthalene (1.11 g, 5.0 mmol) was added, and the solution was refluxed for 3 h. The solution was filtered hot to remove a white precipitate (presumed to be KBr), benzyl bromide (0.58 g, 5.0 mmol) was added, and the mixture was refluxed for an 8 h. The mixture was cooled to room temperature, and the resulting white precipitate was filtered and air-dried (0.74 g, 33 %) . 56.3; H, 3.63; N, 6.15 Synthesis of 1,3-bis(naphthalen-2-ylmethyl)imidazolium bromide (12) Imidazole (0.68 g, 10 mmol) was dissolved in 10 mL of acetonitrile, potassium hydroxide (0.62 g, 11 mmol) was added, and the mixture was heated at reflux for 0.5 h. (2-Bromomethyl)naphthalene (2.21 g, 10 mmol) was added, and the mixture was refluxed for 2.5 h, during that time a white precipitate was formed. The solid was filtered off, and to the filtrate was added a second equivalent of (2-bromomethyl)naphthalene (2.21 g, 10 mmol). The mixture was returned to reflux for 1 h. Volatiles were removed by rotary evaporation under reduced pressure, yielding a viscous brown oil. Hot water (*90°C) was added to the oil, stirred, and slowly decanted. This was repeated several times, and the water layers were combined. A white solid, 12, was precipitated from the cooled water layers and was isolated by filtration and air-dried (1.47 g, 35 % yield Synthesis of 1,3-bis(naphthalen-2-ylmethyl)benzimidazolium bromide (13) Benzimidazole (0.40 g, 3.4 mmol) was dissolved in 5 mL of acetonitrile, potassium hydroxide (0.29 g, 5.1 mmol) was added, and the mixture was stirred for 0.5 h. (2-Bromomethyl)naphthalene (0.82 g, 3.7 mmol) was added, and the solution was refluxed overnight. The solution was filtered hot to remove a white precipitate (presumed to be KBr), the resulting solution was washed into a flask with 2 mL of acetonitrile, a second equivalent of (2-bromomethyl)naphthalene (0.82 g, 3.72 mmol) was added, and the solution was refluxed overnight. The resulting off-white precipitate was collected and washed with ethyl ether and air-dried (1.35 g, 84 % yield Synthesis of 1,3,9-trimethyl-7-(naphthalen-2-ylmethyl)xanthinium iodide (15) Compound 14 (2.90 g, 9.1 mmol) was dissolved in 15 mL of DMF, iodomethane (10 mL, 160 mmol) was added, and the mixture was heated at 80°C for 20 h. Volatiles were removed via rotary evaporation to produce a dark brown oil. The oil was washed with cold acetone to precipitate a light yellow powder. The precipitate was collected and washed with 50 mL of chloroform and 50 mL of water to yield 15 (2.44 g, 58 % yield Synthesis of 1-(2-ethyl-1-naphthyl)-4,5-dichloroimidazole (16) 4,5-Dichloroimidazole (0.14 g, 1.0 mmol) was dissolved into 1 mL of acetonitrile, potassium hydroxide (61 mg, 1.1 mmol) was added, and the mixture was stirred for 0.5 h. 1-(2-Bromoethyl)naphthalene (0.14 mL, 0.24 g, 1.0 mmol) was added, and the solution was refluxed for 2.5 h. The solution was filtered hot to remove a white precipitate (presumed to be KBr), and the solution was allowed to cool to room temperature to yield a tan crystalline material that was isolated by filtration and air-dried (0.09 g, 29 % yield Synthesis of 4,5-dichloro-1,3-bis(2-(naphthalen-1-yl)ethyl)-imidazolium bromide (17) Compound 16 (0.52 g, 1.7 mmol) was dissolved in 2 mL of acetonitrile and combined with 1-(2-Bromoethyl)-naphthalene (1.28 mL, 2.1 g, 9.0 mmol) in a pressure tube. The mixture was heated to 120°C overnight and was then allowed to cool to room temperature. The volatiles were removed via rotary evaporation, and the resulting tan solid was washed with acetonitrile. The resulting solid was then collected, washed with ethyl ether, and dried to yield 17. (0.43 g, 48 % yield 
